European Journal of Cancer and Clinical Oncology
Volume 27, Issue 6, June 1991, Pages 750-755
Specialist interest articleA randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia
References (27)
- et al.
Treatment of acute myelocytic leukemia: a study of Cancer and Leukemia Group B
Blood
(1981) - et al.
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study
Blood
(1982) - et al.
Principal results of the medical research council 8th acute myeloid leukaemia trial
Lancet
(1986) - et al.
Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia
Eur J Cancer Clin Oncol
(1987) Estimate of overall treatment results in acute non lymphocytic leukemia based on age specific rates of incidence and of complete remission
Cancer Treat Rep
(1985)Aging, natural death and the comprehension of morbility
N Engl J Med
(1980)- Adler WH. Aging and immune function. In: Behnke JA, ed. The Biology of Aging. Plenum Press, New York,...
- et al.
Full versus attenuated dose daunorubicin, cytosine arabinoside and 6-thioguanine in the treatment of acute non lymphocytic leukemia in the elderly
J Clin Oncol
(1984) - et al.
Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7, 9 diepidaunorubicin and their anomers
Cancer Treat Rep
(1976) Experimental evaluation of anthracycline analogues
Cancer Treat Rep
(1979)
Antileukemic activity of 4-demethoxydaunorubicin in mice
Tumori
(1980)
Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin
4-demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias
Cited by (95)
Critical Updates to the Leukemia Stem Cell Model
2016, Cancer Stem Cells: Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy ResistanceTreatment of Acute Myeloid Leukemia in Elderly Patients—A Therapeutic Dilemma
2016, Journal of the American Medical Directors AssociationCitation Excerpt :Several studies carried out more than 2 decades ago established an induction regimen of 45 mg/m2 intravenous daunorubicin for 3 days combined with 100 mg/m2 cytarabine by continuous infusion for 7 days (frequently referred to as the “7 + 3” regimen)35–38 as the most commonly applied treatment standard in the US and worldwide. Interestingly, for patients younger than 55–60 years of age, multiple prospective randomized studies demonstrated that other anthracyclines were at least as effective as daunorubicin at a dose of 45 mg/m2.39–47 However, the results for patients older than 55–60 years of age are equivocal.
Presented in part at the 20th Congress of the International Society of Hematology, Milan, 1988.
Copyright © 1991 Published by Elsevier Ltd.